HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lotze, T. E. Articles by Wilfong, A. A. Search for Related Content PubMed PubMed Citation Articles by Lotze, T. E. Articles by Wilfong, A. A.

Zonisamide treatment for symptomatic infantile spasms

From Texas Children’s Hospital, Baylor College of Medicine, Houston, TX.

Address correspondence and reprint requests to Dr. A.A. Wilfong, Division of Child Neurology, Texas Children’s Hospital, Baylor College of Medicine, 6621 Fannin, Suite CC1710, Houston, TX 77030; e-mail: awilfong{at}bcm.tmc.edu

The authors evaluated zonisamide for symptomatic infantile spasms in 23 patients. Spasm cessation, EEG evolution, and tolerability were assessed for a mean duration of 6.5 months. Six patients (26%) had complete control with cessation of spasms and clearing of hypsarrhythmia. Mean latency time from onset of zonisamide treatment to complete spasm control was 19 days. There were no discontinuations due to adverse effects.

Received March 23, 2003. Accepted in final form September 17, 2003.

Dr. Wilfong is on the Speakers Bureau for Elan Pharmaceuticals, Inc.

This article has been cited by other articles:

				S. A. Hosain, S. Merchant, G. E. Solomon, and A. Chutorian Topiramate for the Treatment of Infantile Spasms J Child Neurol, January 1, 2006; 21(1): 17 - 19. [Abstract] [PDF]